{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:19:49Z","timestamp":1772083189438,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"South Egypt Cancer Institute"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.leukres.2013.11.012","type":"journal-article","created":{"date-parts":[[2013,11,24]],"date-time":"2013-11-24T10:38:19Z","timestamp":1385289499000},"page":"243-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["p-Stat3 and bcr\/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Douaa","family":"Sayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosny","family":"Badrawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed R.","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.11.012_bib0005","first-page":"1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2013.11.012_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/leu.2008.246","article-title":"Targeting the leukemic stem cell: the Holy Grail of leukemia therapy","volume":"23","author":"Misaghian","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.11.012_bib0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/asheducation-2008.1.436","article-title":"Chronic myeloid leukemia stem cells","volume":"2008","author":"Jamieson","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2013.11.012_bib0020","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.11.012_bib0025","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1349-7006.2010.01584.x","article-title":"Novel therapeutic approach to eradicatetyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells","volume":"101","author":"Naka","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.leukres.2013.11.012_bib0030","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4161\/cc.8.21.9852","article-title":"The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia","volume":"8","author":"Chen","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.leukres.2013.11.012_bib0035","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1182\/blood-2010-04-280123","article-title":"Stat3 signaling in acute myeloid leukemia: ligand-dependent and independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor","volume":"117","author":"Redell","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.012_bib0040","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.1164551","article-title":"Function of mitochondrial Stat3 in cellular respiration","volume":"323","author":"Wegrzyn","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.leukres.2013.11.012_bib0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.leukres.2013.11.012_bib0050","first-page":"30","article-title":"Role of STAT3 in transformation and drug resistance in CML","volume":"2","author":"Nair","year":"2012","journal-title":"Front Oncol J"},{"key":"10.1016\/j.leukres.2013.11.012_bib0055","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.leukres.2013.11.012_bib0060","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management Recommendations of the European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.11.012_bib0065","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.012_bib0070","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","article-title":"Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression","volume":"86","author":"Gaiger","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.012_bib0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2141.2001.02558.x","article-title":"Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory","volume":"113","author":"Holyoake","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.11.012_bib0080","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood.V99.5.1627","article-title":"Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation","volume":"99","author":"Hevehan","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.012_bib0085","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1189\/jlb.1206766","article-title":"Conditional overexpression of Stat3 in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern","volume":"82","author":"Redell Michele","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.leukres.2013.11.012_bib0090","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward bcr-abl inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.leukres.2013.11.012_bib0095","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2011.12.002","article-title":"Potentiation of Nilotinib mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML","volume":"36","author":"Nair","year":"2012","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.leukres.2013.11.012_bib0100","doi-asserted-by":"crossref","first-page":"e55509","DOI":"10.1371\/journal.pone.0055509","article-title":"Imatinib Reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-\u03baB and HSP27\/p38\/AKT pathways and by inhibiting ABCB1","volume":"8","author":"Sims","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2013.11.012_bib0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2006.06161.x","article-title":"bcr-abl activates STAT3 via JAK and MEK pathways in human cells","volume":"134","author":"Coppo","year":"2006","journal-title":"Br J Haematol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261300413X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261300413X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:34Z","timestamp":1758934714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261300413X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S014521261300413X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.11.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p-Stat3 and bcr\/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}